Previous 10 | Next 10 |
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) is one of today's top gainers. The company's shares are currently up 20.94% on the day to $21.57. Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the tre...
2023-08-01 10:04:48 ET Gainers: Adamis Pharmaceuticals ( ADMP ) +71% . ABVC BioPharma ( ABVC ) +49% . EQRx ( EQRX ) +18% . Rhythm Pharmaceuticals ( RYTM ) +17% . Esperion Therapeutics ( ESPR ) +6% . Losers: TG Therapeu...
2023-08-01 07:15:14 ET Rhythm Pharmaceuticals press release ( NASDAQ: RYTM ): Q2 GAAP EPS of -$0.82 misses by $0.04 . Revenue of $19.2M (+111.9% Y/Y) beats by $4.17M . For further details see: Rhythm Pharmaceuticals GAAP EPS of -$0.82 misses by $0.04, rev...
2023-08-01 07:14:08 ET Rhythm Pharmaceuticals press release ( NASDAQ: RYTM ): Q2 GAAP EPS of -$0.82 misses by $0.04 . Revenue of $19.22M (+112.1% Y/Y) beats by $4.19M . Net product revenues relating to global sales of IMCIVREE were $19.2 million for the second ...
-- Second quarter 2023 net revenue of $19.2 million from global sales of IMCIVREE ® (setmelanotide) -- -- Strong U.S. commercial progress continues with more than 125 new prescriptions for Bardet-Biedl syndrome (BBS) in 2Q 2023, more than 425 since FDA approval -- ...
2023-07-31 14:51:15 ET Rhythm Pharmaceuticals ( NASDAQ: RYTM ) is scheduled to announce Q2 earnings results on Tuesday, August 1st, before market open. The consensus EPS Estimate is -$0.78 (+12.4% Y/Y) and the consensus Revenue Estimate is $15.03M (+550.6% Y/Y). Over t...
BOSTON, July 19, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathwa...
BOSTON, July 17, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathwa...
-- Mean BMI reduction of 21.0% from baseline observed in 13 patients at six months, showing progression from 16.8% mean BMI reduction at 16 weeks -- -- Phase 3 trial evaluating setmelanotide in acquired hypothalamic obesity ongoing; completion of enrollment expected 1Q 2024 -- BOS...
2023-06-07 19:08:50 ET Summary Today, we check back in on Rhythm Pharmaceuticals, Inc., an entrant into the fast-growing weight management medicine space. The company is simultaneously trying ramp up sales from its franchise drug while advancing it in development for other indicat...
News, Short Squeeze, Breakout and More Instantly...
Rhythm Pharmaceuticals Inc. Company Name:
RYTM Stock Symbol:
NASDAQ Market:
Rhythm Pharmaceuticals Inc. Website:
BOSTON, July 08, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today announced the appointment of Alastair “Al...
- European Commission decision anticipated in the second half of 2024 - BOSTON, June 28, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rar...
2024-06-14 11:22:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...